Table 1.

Summary of the main distinctive features of HHV-8-associated lymphoproliferative conditions.

HHV-8-associated lymphoproliferative disorders	Presentation	HHV-8:LANA /vIL-6	EBV	HIVstatus	Ig rearrangements	CD138	B cell markers: CD20/Pax5
Primary effusion lymphoma (PEL)	effusion	≤ 20%	frequent	+/−	monoclonal	+	-
Extracavitary PEL	solid	≤ 20%	frequent	+/−	monoclonal	+	-
Pseudo-PEL	effusion	≤ 20%	rare	+/−	polyclonal	+/−	variable
Plasmablastic MCD	solid	≤ 20%	rare	+/−	polyclonal	-	+ (33–50%)
MCD withplasmablastic clusters	solid	≤ 20%	rare	+	polyclonal/oligoclonal	-	variable
DLBCL NOS	solid	≤ 20%	rare	+	monoclonal	-	+ (33–50%)
GLPD	solid	>70%	frequent	−	polyclonal	-	-

Abbreviations: LANA: latency-associated nuclear antigen; vIL-6: viral interleukin 6; MCD: multifocal Castleman’s disease; DLBCL NOS: diffuse large B-cell lumphoma not otherwise specified; GLPD: germinotropic lymphoproliferative disorder.